Silence Therapeutics plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SLN | ADRX | 2257.HK | BNTC | PMRA.F | SRPT | |
|---|---|---|---|---|---|---|
| Market cap | 1.23B | 1.66B | 463.71M | 323.77M | 1.17B | 2.01B |
| P/E (TTM) | — | — | — | — | 17.3 | — |
| Forward P/E | -52.1 | -9.9 | — | -1.0 | — | 7.8 |
| Price/book | 24.3 | -0.7 | -9.5 | 1.8 | 5.0 | 1.3 |
| Dividend yield | — | — | — | — | 1.54% | — |
| 1-year change | +216.99% | −22.69% | −51.51% | −46.77% | −9.28% | +7.65% |
| Today | +0.10% | −7.02% | −0.12% | +10.48% | +6.01% | +2.43% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SLN news ›Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026
BioSpace Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 LONDON--(BUSINESS WIRE)--$SLN #SenseofSilence--Sil
Silence Therapeutics (SLN) Set to Announce Earnings on Thursday
Posted by Mitch Edgeman on Nov 3rd, 2026 NASDAQ SLN opened at $19.76 on Tuesday. The firm’s 50 day moving average is $13.61 and its 200-day moving average is $9.11. The company has a market capitalization of $1.19 billion, a PE ratio of…
Silence Therapeutics (NASDAQ:SLN) & Connect Biopharma (NASDAQ:CNTB) Critical Survey
Posted by Kim Johansen on Oct 28th, 2026 Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
Silence Therapeutics plc (OTCMKTS:SLNCF) Stock Short Interest Drops 94.2%
Posted by Danessa Lincoln on Oct 28th, 2026 Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 136 shares, a…
Merck KGaA makes noise in hematology with $1.1B Silence buy
Germany’s Merck KGaA is making a commotion in the rare disease space with the $1.1 billion acquisition of RNA specialist Silence Therapeutics and the biotech’s Phase 3 asset for polycythemia vera divesiran. The deal gives Merck KGaA “an…
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
lincolnjournal.com Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (âKSFâ) are inve
Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
21 October 2026 | Wednesday | News Merck, a leading science and technology company, announced its entry into a definitive agreement to acquire Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company…
Merck turns up the volume on rare disease with $1.3bn Silence Therapeutics buy
Germany’s Merck has agreed to acquire London-based Silence Therapeutics in an all-cash deal, adding a late-stage rare blood cancer asset to its pipeline. Shareholders of Silence Therapeutics will receive $20.00 per American Depositary…
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Published on 10/19/2026 at 08:45 am EDT Germany's Merck KGaA said it agreed to buy U.K. biotech company Silence Therapeutics for $1.3 billion, adding an experimental medicine for rare disease polycythemia vera to its drug pipeline. Merck…
More from 4 other outlets
- european-biotechnology.com Merck to buy siRNA specialist Silence Therapeutics for $1.3 billion
- Briefs Finance Merck KGaA agrees to buy Silence Therapeutics for roughly $1.1 billion
- PYMNTS.com Merck to Buy Silence Therapeutics for $1.3 Billion in RNA Drug Push
- PharmExec Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion.
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion on October 18, 2026. The purchase price of $20 per ADS in cash, with each ADS representing three... Merck KGaA (XTRA:MRK) entered into…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com15
- themarketsdaily.com7
- stocktitan.net4
- seekingalpha.com2
- biopharmaapac.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 49 articles, not a forecast.